Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Yogurt improves insulin resistance, liver fat in obese women with NAFLD, MetS

03 Jun 2019
There's a way to make yogurt even more of a superfood - use a clay pot for the fermentation process.

Eating yogurt appears to be better than drinking milk at improving insulin resistance (IR) and liver fat in obese women with nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS), a China study has shown. Yogurt ameliorates IR by enhancing lipid metabolism, reducing inflammation, oxidative stress and lipopolysaccharides (LPS), and changing the gut microbiota composition.

The investigators randomized 100 obese women aged 36–66 years with both NAFLD and MetS to consume 220 g/d of either conventional yogurt or milk for 24 weeks. Anthropometric indices, serum glucose, insulin, lipids and cytokines in all participants, as well as liver fat and gut microbiota in 20 participants randomly selected from each group, were measured at baseline and week 24.

Of the participants, 48 from the yogurt group and 44 from the milk group completed the intervention. Those who consumed yogurt, compared with milk, had significantly reduced homeostasis model assessment of IR (–0.53, 95 percent CI, –1.03 to –0.02), fasting insulin (–2.77 mU/L, –4.91 to –0.63 mU/L), 2-h insulin (–25.5 mU/L, –33.0 to –17.9 mU/L), 2-h area under the curve for insulin (–29.4 mU/L · h, –44.0 to –14.8 mU/L · h), alanine aminotransferase (–4.65 U/L, –8.67 to –0.64 U/L), intrahepatic lipid (–3.44 percent, –6.19 to –0.68 percent) and hepatic fat fraction (–3.48, –6.34 to –0.63 percent).

The yogurt group also had decreased serum LPS (–0.31 EU/mL, –0.48 to –0.14 EU/mL), fibroblast growth factor 21 (–57.76 pg/mL, –86.32 to –29.19 pg/mL), lipids, and biomarkers of inflammation and oxidative stress, and altered gut microbiota composition. In mediation analysis, yogurt appeared to improve IR by reducing serum lipids, inflammation, oxidative stress and LPS.

“Because consumption of conventional yogurt has beneficial effects in a healthy population, and IR is the mutual pathogenesis in NAFLD and MetS, we hypothesized that yogurt would ameliorate IR in patients with NAFLD and MetS,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.